Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
05/2003
05/14/2003CN1416874A Medicated pillow and its making process
05/14/2003CN1416852A Active matter for preventing and treating cerebral diseases and promoting intelligence growth and its prepn
05/14/2003CN1416839A Prepn of xuelukang oral liquid
05/14/2003CN1416817A Breviscapine dispersing tablet and its prepn
05/14/2003CN1108301C Inhibitors of microsomal triglyceride transfer protein and mothed
05/14/2003CN1108168C Chinese medicine preparation for treating angina pectoris and its dispensation process
05/13/2003WO2002040048A2 Recombined anti-gpiib/iiia antibodies used for inhibiting angiogenesis
05/13/2003US6562988 16-HETE (16-hydroxyeicosatetraenoic acid) analogues such as the methanesulfonamide ester (-CO-NH-SO2-CH3); inhibiting neutrophil adhesion and neutrophil aggregation; treating stroke, inflammatory diseases
05/13/2003US6562976 Such as methyl-2-cyclopentyl-4-(4-fluorophenyl)-5-oxo-7,7-dimethyl-1,4,5,6,7,8 -hexahydroquinoline-3-carboxylate for treatment of arteriosclerosis and dyslipidaemias; condensation
05/13/2003US6562872 Emulsion of perfluoroorganic compounds for medical purposes, a process for the preparation thereof and methods for treating and preventing diseases with the use thereof
05/13/2003US6562866 A method for treating or preventing an elevated blood lipid level-related disease in a mammal, which comprises administering thereto an effective amount of rutin, quercetin or a mixture thereof.
05/13/2003US6562864 Catechin multimers as therapeutic drug delivery agents
05/13/2003US6562860 Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications
05/13/2003US6562851 Antiinflammatory and antiasthmatic agents; inhibitors of alpha4 beta1 mediated cell adhesion
05/13/2003US6562846 Bisarylimidazolyl fatty acid amide hydrolase inhibitors
05/13/2003US6562843 For treating disorders ameliorated by a reduction in TNF-alpha production and/or p38 activity, and are therefore useful for treating inflammatory disorders such as rheumatoid arthritis, as well as AIDS-related disorders
05/13/2003US6562837 Use of tetrahydroisoquinoline compounds for the treatment of septicemia
05/13/2003US6562831 Inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases
05/13/2003US6562826 To maintain human ranolazine plasma levels at therapeutic levels
05/13/2003US6562825 For treating inflammatory disease including asthma and allergic diseases, as well as autoimmune pathologies
05/13/2003US6562824 Dihydropyridine soft drugs, and related compositions and methods
05/13/2003US6562823 Inhibition of farnesyl-protein transferase has been shown to block the growth of Ras-transformed cells in soft agar
05/13/2003US6562814 3-thioxo-[1,2,4]-oxadiazinan-5-one derivatives
05/13/2003US6562811 Pyridine derivatives
05/13/2003US6562799 DNA binding proteins that are modified such that they are stable under non-hypoxic as well as hypoxic conditions
05/13/2003US6562613 Recombinant C-proteinase and processes, methods and uses thereof
05/13/2003US6562381 (+)-Cycloolivil as antioxidant obtained from natural source namely stereospermum personatum
05/13/2003US6562344 Nitrosylation of protein SH groups and amino acid residues as a therapeutic modality
05/13/2003US6562330 Gelling polyacrylate with pendant zwitterionic groups and counterion component in body cavity; improving biocompatibi-lity; such as embolizing vein or packing aneurysm
05/13/2003CA2428649A1 Recombined anti-gpiib/iiia antibodies used for inhibiting angiogenesis
05/13/2003CA2202992C Heterocycle substituted propenoic acid derivatives as nmda antagonists
05/13/2003CA2127876C Imidazole derivatives and their use as cytokine inhibitors
05/09/2003CA2464707A1 Compositions for treatment of postmenopausal female sexual dysfunction
05/09/2003CA2406687A1 Chimeric promoters for controlling expression in muscle cells
05/08/2003WO2003038123A2 Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
05/08/2003WO2003038110A2 7118, a human arginine n-methyltransferase family member and uses therefor
05/08/2003WO2003038100A1 Methods and means for producing proteins with predetermined post-translational modifications
05/08/2003WO2003038071A1 Detection of haematopoietic stem cells and progeny and uses thereof
05/08/2003WO2003038058A2 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
05/08/2003WO2003038043A2 Combinations of dr5 antibody and other therapeutic agents
05/08/2003WO2003038037A2 Glycogen synthase kinase function in endothelial cells
05/08/2003WO2003037916A2 Linear basic compounds having nk-2 antagonist activity and formulations thereof
05/08/2003WO2003037913A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
05/08/2003WO2003037905A1 Silicon compounds
05/08/2003WO2003037901A1 Bridged bicycle (1,4) benzodiazepine vasopressin receptor antagonists
05/08/2003WO2003037899A1 Pde9 inhibitors for treating cardiovascular disorders
05/08/2003WO2003037898A1 Pyrimido [4,5-b] indole derivatives
05/08/2003WO2003037892A1 Compounds useful as reversible inhibitors of cysteine proteases
05/08/2003WO2003037888A1 3-substituted-4-pyrimidone derivatives
05/08/2003WO2003037887A1 Therapeutic isoquinoline compounds
05/08/2003WO2003037879A1 Substituted (1h)-quinoxalin-2-one compounds and substituted 4-aryl- and 4-heteroarylcyclohexane compounds
05/08/2003WO2003037876A1 Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
05/08/2003WO2003037874A1 An efficient synthesis of 5-heteroatom-containing-pyrazoles
05/08/2003WO2003037872A1 Therapeutic quinoline compounds with 5-ht-antagonistic properties
05/08/2003WO2003037871A1 Therapeutic quinolone compounds with 5-ht-antagonistic properties
05/08/2003WO2003037870A1 Substituted 1h-quinolin-2-one compounds
05/08/2003WO2003037860A2 Purine analogs having hsp90-inhibiting activity
05/08/2003WO2003037853A1 Substituted thioacetamides
05/08/2003WO2003037852A1 Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
05/08/2003WO2003037847A1 Benzamide derivatives as antagonists of orexin receptors
05/08/2003WO2003037433A1 Co-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists
05/08/2003WO2003037432A1 Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
05/08/2003WO2003037397A2 Drug eluting radially expandable tubular stented grafts
05/08/2003WO2003037384A2 Polymer conjugates of protein kinase c inhibitors
05/08/2003WO2003037376A1 Preventives and/or remedies for post-transplant arteriosclerosis as rejection of organ transplant
05/08/2003WO2003037363A2 Non-neurotoxic plasminogen activating factors for treating stroke
05/08/2003WO2003037362A2 Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism
05/08/2003WO2003037361A2 Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
05/08/2003WO2003037352A1 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders
05/08/2003WO2003037351A1 Heterocyclo-alkylsulfonyl pyrazoles and their use as cox-2 inhibitors
05/08/2003WO2003037349A1 Type 4 phosphodiesterase inhibitors and uses thereof
05/08/2003WO2003037336A1 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer
05/08/2003WO2003037335A1 5-heteroatom-substituted pyrazoles
05/08/2003WO2003037332A1 Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
05/08/2003WO2003037330A1 Sulfonyl-and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors
05/08/2003WO2003037325A1 Hydroxy substituted amides for the treatment of alzheimer's disease
05/08/2003WO2003037324A1 Use of an opuntia ficus-indica extract and compounds isolated therefrom for protecting nerve cells
05/08/2003WO2003037320A1 Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect
05/08/2003WO2003037316A1 Peroxisome proliferator activated receptor ligands and process for producing the same
05/08/2003WO2003037308A2 Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion
05/08/2003WO2003037301A2 Oral dosage forms for improving the bioavailability of therapeutic agents
05/08/2003WO2003037296A2 Methods and dosage forms for improving the bioavailability of therapeutic agents
05/08/2003WO2003037268A2 Hepta-, octa- and nonapeptides having antiangiogenic activity
05/08/2003WO2003037266A2 Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity
05/08/2003WO2003037220A1 Improved endoprosthetic device
05/08/2003WO2003037168A2 Methods and formulations for minimizing spasticity in blood vessel grafts
05/08/2003WO2003037166A2 Devices and methods for the restoration of a spinal disc
05/08/2003WO2003037165A2 System and method for the pretreatment of the endplates of an intervertebral disc
05/08/2003WO2003020254A8 Pharmaceutical composition comprising (-)-secoisolariciresinol
05/08/2003WO2003012105A3 Vegf isoform
05/08/2003WO2003009805A3 Analgesic methods using endothelin receptor ligands
05/08/2003WO2003002595A3 Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
05/08/2003WO2002094377A3 Pharmaceutical preparation comprising physiologically acceptable potassium and magnesium salts and use thereof for the prophylaxis and treatment of qt-interval extension
05/08/2003WO2002090524A3 Isolated nucleic acid molecules encoding a novel human signal transducing kinase-mapkap-2; encoded proteins, cells transformed therewith and uses thereof
05/08/2003WO2002085414A3 Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
05/08/2003WO2002083076A3 Method for inhibiting atherosclerotic plaque formation
05/08/2003WO2002081499A3 Somatostatin agonists
05/08/2003WO2002072608A3 POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS
05/08/2003WO2002060897A3 Process for making substituted 8-arylquinolinium benzenesulfonate
05/08/2003WO2002057226A3 68730 and 69112 protein kinase molecules and uses therefor
1 ... 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 ... 1595